A startup developing allogeneic T-cell therapies from pluripotent stem cells to provide novel treatments for advanced and recurrent cancers and immune-related diseases. Aiming to deliver the potential for a cure to diseases that were previously difficult to treat.
We are conducting clinical development of an oral therapeutic cancer vaccine. We have completed a Phase I clinical trial targeting urothelial carcinoma and are currently conducting a Phase I/IIa clinical trial for malignant pleural mesothelioma.
At Beef Sommelier, we provide our B-som Diagnosis with the aim of creating a world where producers can raise their ideal cattle and consumers can enjoy beef that truly matches their preferences. Our technology not only quantifies biological information from beef cattle, but also supports producers in achieving their target meat quality. By introducing a new scientific perspective that goes beyond conventional standards, we make the “unseen qualities” of beef visible and measurable. This enables consumers to clearly understand the characteristics of the beef they choose. B-som is the world’s first scientific diagnostic service that bridges the gap between producers and consumers.
HOIST is developing anti-cancer products with novel mechanism-of-action utilizing the MA-T® system. Further, we are pursuing epitranscriptomics drug discovery via a novel target, ALKBH. In addition, we run a drug discovery support business for our clients creating patient derived cells (PDC) / patient derived xenografts (PDX). In pharmaceutical development, HOIST aims to utilize partnerships with pharmaceutical companies (via licensing-out, joint drug discovery etc.). In the drug discovery support business, we tailor PDC/PDX solutions to individual needs of our clients, and contribute to higher success rate of product development.
A startup developing mass-producible platelet preparations using technology to generate platelets from human iPS cells. It aims to provide stable supplies to medical settings in developed and developing countries facing blood donation shortages, thereby supporting transfusion medicine.